Valsartan, 320mg, 30 tablets per bottle, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46256. NDC: 51655-0654-52
Published August 22, 2018 · Recall initiated: July 18, 2018
Summary
FDA records drug Class II recall D-1098-2018, published August 22, 2018 and initiated July 18, 2018. Recalling firm: Northwind Pharmaceuticals LLC; Status: Terminated; Reported quantity: 14 bottles; Lot: Lot: UT48100001, exp 9/30/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Northwind Pharmaceuticals LLC
- Distributor
- Indiana
- Lot
- Lot: UT48100001, exp 9/30/2019
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDASulfamethoxazole and Trimethoprim Tablets, USP 800mg / 160mg Double Strength packaged in a) 6-count bottlesSeptember 24, 2025
- FDABusPIRone Hydrochloride Tablets USP, 7.5 mg, 30-count bottles, Rx Only, Repackaged By: NOrthwindMay 3, 2023
- FDAGlimepiride Tablets, USP 2mg, packaged in a) 30-count bottles (NDC 51655-383-52), and b)90-count bottles (NDCMay 3, 2023
- FDATadalafil Tablets, USP 20 mg, packaged in a) 6-count bottles (NDC 51655-473-87), and b) 15-count bottles (NDCMay 3, 2023
- FDAValsartan HCTZ, 160/12.5mg, 30 tablets per bottle, Rx Only, Repackaged By: Northwind Pharmaceuticals,August 22, 2018
- FDAContrave (naltrexone HCl and bupropion HCl) Extended-Release Tablets, 8 mg/90 mg, 120-count bottle, Rx only,August 22, 2018
Questions about this recall
Was Valsartan, 320mg, 30 tablets per bottle, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46256. NDC: 51655-0654-52 recalled?
Yes. FDA published recall D-1098-2018 on August 22, 2018. Reported hazard: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
What should I do if I have this product?
Voluntary: Firm initiated · Letter